Paclitaxel Injection Market Size, Share, Growth Analysis Report By Indication (Breast Cancer, Prostate Cancer, Testicular Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Others), By End User (Cancer Research Institutes, Hospitals, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Intelligence, Trends, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Pfizer
- Celgene Corporation
- Fresenius Kabi Oncology Ltd
- Others
Reports Description
The “Global Paclitaxel Injection Market” to 2030 was estimated at nearly USD 4.5 billion in 2021. As per our study, the market is anticipated to reach a value of USD 11.4 billion by 2030 showing a CAGR of 13%. Scrutinizing the uncertainties of the COVID-19 pandemic, our research team is constantly tracking and assessing the impact of the pandemic on the Paclitaxel Injection Market. These comprehensive insights are included in our market search report as a key market contributor.
The global Paclitaxel Injection Market research report offers an in-depth analysis of the global market size, which is further segmented into regional and country-level market size, and segmentation market growth. Also, it provides the market share, sales analysis, competitive landscape, the impact of domestic and global market participants, trade regulations, value chain optimization, recent key developments, strategic market growth analysis, opportunities analysis, product launches, and technological innovations.
Paclitaxel Injection Market: Overview
The chemotherapy drug paclitaxel, also referred to as Taxol, stops the growth of cancer cells and slows down their spread throughout the body. It functions by halting the development of cancerous cells and is a member of the antineoplastic medication class. Paclitaxel is more successful than other drugs at slowing the spread of cancer, and it is also readily available on the market, all of which contribute to its high demand.
Paclitaxel Injection Market: COVID–19 Impact Analysis
The COVID-19 pandemic presents ongoing difficulties and restricts a number of medical examinations. The number of people who could evaluate their symptoms was constrained due to the possibility of the virus spreading. The COVID-19 outbreak thus had a detrimental effect on the market for paclitaxel injection as a whole. The market is anticipated to be pulled by vaccination campaigns and a reduction in COVID-19 restrictions and spread.
The research presents the impact of the pandemic and recovery for Paclitaxel Injection for the predicted period up to 2030. For firms to rearrange their resources to function within the limitations of the pandemic, the study paper presents three market recovery scenarios: Low Growth, Reference Case, and High Growth. The cases take into account the impact on consumer confidence, supply chain disruptions, and the economy.
Paclitaxel Injection Market: Growth Drivers
Growing Cancer Patient Population
One of the main factors propelling the expansion of the paclitaxel injection market is the rise in cancer patients globally. In 112 out of the 183 nations evaluated in 2019, cancer was rated as the leading or second primary cause of death for those under 70. Furthermore, it was the third or fourth most common cause in other nations.
There are more cancer patients globally due to the rising use of alcohol and tobacco. Since paclitaxel is one of the main medications used to treat cancer patients, it is projected that the rise in cancer cases will increase the demand for paclitaxel injections.
Increased spending and infrastructure developments in healthcare
A rise in investments, particularly those made by governments, is one of the key factors influencing market expansion. The Peter G. Peterson Foundation study found that healthcare spending in the US has dramatically increased. National healthcare spending is projected to reach USD 6.2 trillion by the end of 2028. The American Medical Association also predicts a 9.7% increase in US healthcare spending to USD 4.1 trillion in 2020. This growth rate is significantly higher than the 4.3% projection for 2019.
Market segmentation for paclitaxel injections:
The indication and end user segments of the paclitaxel injection market are separated. In terms of indication, the breast cancer market for paclitaxel injections was the largest globally in 2021.
The expansion of the paclitaxel injection market is being driven by the rising prevalence of breast cancer in females. The International Organization for Research on Cancer reports that breast cancer has surpassed lung cancer as the most prevalent type of cancer to be diagnosed. In addition, breast cancer accounted for 11.7% of all new cancer cases in 2020. As a result, it is projected that both the prevalence of breast cancer and public understanding of the value of paclitaxel injection in the management of the condition would rise.
Report Scope
| Feature of the Report | Details |
| Market Size in 2021 | USD 4.5 Billion |
| Projected Market Size in 2030 | USD 11.4 Billion |
| CAGR Growth Rate | 13% CAGR (2022-2030) |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Prominent Players | Pfizer, Celgene Corporation, Fresenius Kabi Oncology Ltd, Abbott Laboratories, Onco Therapies Ltd (Strides Arcolab Ltd.), Sagent Pharmaceuticals, Bristol Myers Squibb, Luye Pharma Group, NOVASEP, and Others |
| Key Segment | By Indication, End User, and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Key Insights:
- The paclitaxel injection market is predicted to expand annually at a CAGR of roughly 13% over the projected period, according to the study supplied by our research analyst (2022-2030).
- The global market for paclitaxel injection was estimated to be worth USD 4.5 billion in 2021 and is anticipated to grow to USD 11.4 billion by 2030. The market is expected to grow significantly over the coming years as a result of a number of driving factors.
- According to indication segmentation, it was predicted that the breast cancer category would hold the most market share in 2021.
- In 2021, the hospital segment was the top revenue-generating sector according to end-user segmentation.
- The North American region generated the most revenue in 2021, according to the region.
New Development
- BioPharma, Inc. was designated as ProPhase Laboratories, Inc.’s wholly-owned subsidiary in July 2022. Moreover, ProPhase BioPharma, Inc. (PBIO) and Global BioLife, Inc. have inked a license agreement for the Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant promise across various therapeutic areas. Co-therapy for paclitaxel will be one of the company’s primary emphasis areas.
- According to a joint press release from Innovent Biologics, Inc. and Eli Lilly and Company, the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application for TYVYT in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of cancer, autoimmune, metabolic, ophthalmology, and other serious diseases.
Regional Landscape
North America dominated the market for paclitaxel injection in 2021. All around North America, cancer is becoming more common. According to Cancer.org, there will be over 1.8 million new instances of cancer in the US in 2020 and roughly 606,520 cancer deaths.
The rise of the market in North America has been facilitated by the availability of an updated and modernised healthcare infrastructure, increased healthcare spending, and a high degree of awareness regarding the accessibility of cutting-edge treatments and pharmaceuticals, such as paclitaxel injection.
Competitive Environment
The Paclitaxel Injection Market Research profiles a number of important companies in the Paclitaxel Injection market and offers details on their competitive strategies and teamwork. The full research presents a two-layered picture of the market. By comprehending the global revenue of participants, the global cost of production, and the creation by manufacturers during the forecast period of 2022 to 2030, the reader may distinguish between the perceptions of manufacturers in the Paclitaxel Injection market.
The global Paclitaxel Injection Market is segmented as follows:
By Indication
- Breast Cancer
- Prostate Cancer
- Testicular Cancer
- Non-Small Cell Lung Cancer
- Lung Cancer
- Others
By End User
- Cancer Research Institutes
- Hospitals
- Others
On the basis of Geography
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Paclitaxel Injection Market, (2022 – 2030) (USD Billion)
- 2.2 Global Paclitaxel Injection Market: snapshot
- Chapter 3. Global Paclitaxel Injection Market – Industry Analysis
- 3.1 Paclitaxel Injection Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Rise in the Number of Cancer Patients
- 3.2.2 Driver 2
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Indication
- 3.7.2 Market attractiveness analysis By End User
- Chapter 4. Global Paclitaxel Injection Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Paclitaxel Injection Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Paclitaxel Injection Market – Indication Analysis
- 5.1 Global Paclitaxel Injection Market overview: By Indication
- 5.1.1 Global Paclitaxel Injection Market share, By Indication, 2021 and 2030
- 5.2 Breast Cancer
- 5.2.1 Global Paclitaxel Injection Market by Breast Cancer, 2022 – 2030 (USD Billion)
- 5.3 Prostate Cancer
- 5.3.1 Global Paclitaxel Injection Market by Prostate Cancer, 2022 – 2030 (USD Billion)
- 5.4 Testicular Cancer
- 5.4.1 Global Paclitaxel Injection Market by Testicular Cancer, 2022 – 2030 (USD Billion)
- 5.5 Non-Small Cell Lung Cancer
- 5.5.1 Global Paclitaxel Injection Market by Non-Small Cell Lung Cancer, 2022 – 2030 (USD Billion)
- 5.6 Lung Cancer
- 5.6.1 Global Paclitaxel Injection Market by Lung Cancer, 2022 – 2030 (USD Billion)
- 5.7 Others
- 5.7.1 Global Paclitaxel Injection Market by Others, 2022 – 2030 (USD Billion)
- 5.1 Global Paclitaxel Injection Market overview: By Indication
- Chapter 6. Global Paclitaxel Injection Market – End User Analysis
- 6.1 Global Paclitaxel Injection Market overview: By End User
- 6.1.1 Global Paclitaxel Injection Market share, By End User, 2021 and 2030
- 6.2 Cancer Research Institutes
- 6.2.1 Global Paclitaxel Injection Market by Cancer Research Institutes, 2022 – 2030 (USD Billion)
- 6.3 Hospitals
- 6.3.1 Global Paclitaxel Injection Market by Hospitals, 2022 – 2030 (USD Billion)
- 6.4 Others
- 6.4.1 Global Paclitaxel Injection Market by Others, 2022 – 2030 (USD Billion)
- 6.1 Global Paclitaxel Injection Market overview: By End User
- Chapter 7. Paclitaxel Injection Market – Regional Analysis
- 7.1 Global Paclitaxel Injection Market Regional Overview
- 7.2 Global Paclitaxel Injection Market Share, by Region, 2021 & 2030 (USD Billion)
- 7.3. North America
- 7.3.1 North America Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.3.1.1 North America Paclitaxel Injection Market, by Country, 2022 – 2030 (USD Billion)
- 7.3.1 North America Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.4 North America Paclitaxel Injection Market, by Indication, 2022 – 2030
- 7.4.1 North America Paclitaxel Injection Market, by Indication, 2022 – 2030 (USD Billion)
- 7.5 North America Paclitaxel Injection Market, by End User, 2022 – 2030
- 7.5.1 North America Paclitaxel Injection Market, by End User, 2022 – 2030 (USD Billion)
- 7.6. Europe
- 7.6.1 Europe Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.6.1.1 Europe Paclitaxel Injection Market, by Country, 2022 – 2030 (USD Billion)
- 7.6.1 Europe Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.7 Europe Paclitaxel Injection Market, by Indication, 2022 – 2030
- 7.7.1 Europe Paclitaxel Injection Market, by Indication, 2022 – 2030 (USD Billion)
- 7.8 Europe Paclitaxel Injection Market, by End User, 2022 – 2030
- 7.8.1 Europe Paclitaxel Injection Market, by End User, 2022 – 2030 (USD Billion)
- 7.9. Asia Pacific
- 7.9.1 Asia Pacific Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.9.1.1 Asia Pacific Paclitaxel Injection Market, by Country, 2022 – 2030 (USD Billion)
- 7.9.1 Asia Pacific Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.10 Asia Pacific Paclitaxel Injection Market, by Indication, 2022 – 2030
- 7.10.1 Asia Pacific Paclitaxel Injection Market, by Indication, 2022 – 2030 (USD Billion)
- 7.11 Asia Pacific Paclitaxel Injection Market, by End User, 2022 – 2030
- 7.11.1 Asia Pacific Paclitaxel Injection Market, by End User, 2022 – 2030 (USD Billion)
- 7.12. Latin America
- 7.12.1 Latin America Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.12.1.1 Latin America Paclitaxel Injection Market, by Country, 2022 – 2030 (USD Billion)
- 7.12.1 Latin America Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.13 Latin America Paclitaxel Injection Market, by Indication, 2022 – 2030
- 7.13.1 Latin America Paclitaxel Injection Market, by Indication, 2022 – 2030 (USD Billion)
- 7.14 Latin America Paclitaxel Injection Market, by End User, 2022 – 2030
- 7.14.1 Latin America Paclitaxel Injection Market, by End User, 2022 – 2030 (USD Billion)
- 7.15. The Middle-East and Africa
- 7.15.1 The Middle-East and Africa Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.15.1.1 The Middle-East and Africa Paclitaxel Injection Market, by Country, 2022 – 2030 (USD Billion)
- 7.15.1 The Middle-East and Africa Paclitaxel Injection Market, 2022 – 2030 (USD Billion)
- 7.16 The Middle-East and Africa Paclitaxel Injection Market, by Indication, 2022 – 2030
- 7.16.1 The Middle-East and Africa Paclitaxel Injection Market, by Indication, 2022 – 2030 (USD Billion)
- 7.17 The Middle-East and Africa Paclitaxel Injection Market, by End User, 2022 – 2030
- 7.17.1 The Middle-East and Africa Paclitaxel Injection Market, by End User, 2022 – 2030 (USD Billion)
- Chapter 8. Company Profiles
- 8.1 Pfizer
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 Celgene Corporation
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Fresenius Kabi Oncology Ltd
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Abbott Laboratories
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Onco Therapies Ltd (Strides Arcolab Ltd.)
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Sagent Pharmaceuticals
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 Bristol Myers Squibb
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Luye Pharma Group
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 NOVASEP
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.1 Pfizer
List Of Figures
Figures No 1 to 23
List Of Tables
Tables No 1 to 52
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
FAQs
“North America” region will lead the global Paclitaxel Injection market during the forecast period 2022 to 2030.
The surge in the number of cancer patients worldwide is one of the prime drivers for the growth of the paclitaxel injection market.
The key players operating in the Paclitaxel Injection market are Pfizer, Celgene Corporation, Fresenius Kabi Oncology Ltd, Abbott Laboratories, Onco Therapies Ltd (Strides Arcolab Ltd.), Sagent Pharmaceuticals, Bristol Myers Squibb, Luye Pharma Group, NOVASEP, and Others.
The global Paclitaxel Injection market is expanding growth with a CAGR of approximately 13% during the forecast period (2022 to 2030).
The global Paclitaxel Injection market size was valued at USD 4.5 billion in 2021 and it is projected to reach around USD 11.4 billion by 2030.